Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 04/24 08:31:25 pm
64.49 EUR   -2.11%
04/04UCB : Transparency notification The Capital Group Companies Inc
AQ
04/04UCB : Acquisition of own shares
AQ
03/23UCB : Convening notice to attend the general meeting of shareholders..
GL
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
04/18/2018 04/19/2018 04/20/2018 04/23/2018 04/24/2018 Date
67.1(c) 65.62(c) 65.28(c) 65.88(c) 65.48 Last
285 008 271 150 301 197 375 080 499 536 Volume
+1.15% -2.21% -0.52% +0.92% -0.61% Change
More quotes
Financials (EUR)
Sales 2018 4 545 M
EBIT 2018 1 104 M
Net income 2018 757 M
Finance 2018 110 M
Yield 2018 1,89%
Sales 2019 4 719 M
EBIT 2019 1 198 M
Net income 2019 849 M
Finance 2019 632 M
Yield 2019 1,96%
P/E ratio 2018 16,40
P/E ratio 2019 14,46
EV / Sales2018 2,78x
EV / Sales2019 2,57x
Capitalization 12 757 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.The company was founded by Emmanuel Janssen on January 18, 1928 and is... 
Sector
Pharmaceuticals
Calendar
04/24Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
04/05UCB : Patent Issued for Treatment for Bone Diseases (USPTO 9925260)
AQ
04/04UCB : Transparency notification The Capital Group Companies Inc
AQ
04/04UCB : Acquisition of own shares
AQ
03/23UCB : Convening notice to attend the general meeting of shareholders to be held ..
GL
03/23UCB : Extraordinary general shareholder meeting
CO
03/15UCB : Data on Cardiology Detailed by Researchers at UCB S.A. (miR-21-5p as a pot..
AQ
03/08UCB : Patent Issued for Systems and Methods for Administering Medication (USPTO ..
AQ
02/21Arix, Fosun in China-focused deal
AQ
02/16UCB : Advances Psoriasis Pipeline with Positive Data at American Academy &hellip..
PU
02/08UCB : Findings on Therapeutics Research Reported by Investigators at UCB S.A. (U..
AQ
More news
Sector news : Pharmaceuticals - NEC
08:56aASTRAZENECA : Negative Results From Phase 3 Trial of Imfinzi and Tremelimumab
DJ
08:37aASTRAZENECA : to raise stake in Circassia to up to 19.9 percent
RE
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
04/23SUSAN KILSBY : Holding(s) In Company
DJ
04/23INVESCO UK LTD INVESCO LTD. : Form 8.3 - Shire Plc
DJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on UCB 
UCB - 2017
After the accumulation, an upward acceleration ?
BUY
UCB - 2017
Close to a key level on the weekly chart
BUY
More Strategies
Latest Tweets
04/20Belgium-based UCB says it expects to submit an NDA to U.S. regulators before ..
3
04/20UCB offers $370M for Proximagen’s epilepsy spray, with NDA to follow  
04/20UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasa.. 
04/20UCB snags an NDA-ready epilepsy drug from Proximagen in $370M deal
3
04/20UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasa.. 
More tweets
Qtime:47
News from SeekingAlpha
02/23UCB S.A. 2017 Q4 - Results - Earnings Call Slides 
02/22UCB S.A. reports FY results 
01/20YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O.. 
01/19Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket 
01/08EMA accepts UCB's marketing application for osteoporosis med romosozumab 
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 69,2 €
Spread / Average Target 5,0%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB-1.36%15 587
JOHNSON & JOHNSON-9.23%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY7.07%158 571